DDD Partners LLC Sells 114 Shares of Danaher Co. (NYSE:DHR)

DDD Partners LLC lowered its position in shares of Danaher Co. (NYSE:DHR) by 8.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,168 shares of the conglomerate’s stock after selling 114 shares during the quarter. DDD Partners LLC’s holdings in Danaher were worth $270,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Banco Santander S.A. purchased a new position in Danaher during the third quarter valued at approximately $683,000. Parkside Financial Bank & Trust lifted its holdings in shares of Danaher by 4.8% in the third quarter. Parkside Financial Bank & Trust now owns 3,080 shares of the conglomerate’s stock worth $764,000 after buying an additional 142 shares in the last quarter. Keybank National Association OH lifted its holdings in shares of Danaher by 0.5% in the third quarter. Keybank National Association OH now owns 553,155 shares of the conglomerate’s stock worth $137,238,000 after buying an additional 2,567 shares in the last quarter. Kingsview Wealth Management LLC lifted its holdings in shares of Danaher by 1.0% in the third quarter. Kingsview Wealth Management LLC now owns 17,346 shares of the conglomerate’s stock worth $4,303,000 after buying an additional 172 shares in the last quarter. Finally, Lcnb Corp lifted its holdings in shares of Danaher by 21.9% in the second quarter. Lcnb Corp now owns 2,229 shares of the conglomerate’s stock worth $535,000 after buying an additional 400 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on DHR shares. The Goldman Sachs Group downgraded shares of Danaher from a “buy” rating to a “neutral” rating and decreased their price target for the company from $215.00 to $205.00 in a research note on Thursday, December 7th. Royal Bank of Canada boosted their price objective on shares of Danaher from $254.00 to $282.00 and gave the company an “outperform” rating in a research report on Wednesday, January 31st. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Raymond James upped their price target on shares of Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. Finally, JPMorgan Chase & Co. increased their target price on shares of Danaher from $250.00 to $270.00 and gave the stock an “overweight” rating in a report on Wednesday, December 20th. Seven equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $266.00.

Insider Buying and Selling

In other Danaher news, SVP Daniel Raskas sold 23,757 shares of the stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the transaction, the senior vice president now directly owns 38,102 shares in the company, valued at $9,601,704. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Teri List sold 3,289 shares of the stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total transaction of $816,724.48. Following the completion of the sale, the director now directly owns 19,726 shares of the company’s stock, valued at $4,898,360.32. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Daniel Raskas sold 23,757 shares of the stock in a transaction on Monday, February 26th. The stock was sold at an average price of $252.00, for a total value of $5,986,764.00. Following the completion of the transaction, the senior vice president now owns 38,102 shares of the company’s stock, valued at approximately $9,601,704. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 32,957 shares of company stock worth $8,265,802. Company insiders own 11.10% of the company’s stock.

Danaher Stock Up 0.2 %

Shares of NYSE:DHR opened at $248.84 on Thursday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.68 and a quick ratio of 1.37. The firm has a market capitalization of $184.07 billion, a PE ratio of 38.94, a price-to-earnings-growth ratio of 3.77 and a beta of 0.84. The firm’s 50-day moving average is $246.68 and its two-hundred day moving average is $230.40. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $259.00.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, January 30th. The conglomerate reported $2.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $0.18. The company had revenue of $6.41 billion for the quarter, compared to analyst estimates of $6.10 billion. Danaher had a net margin of 17.26% and a return on equity of 12.25%. The business’s revenue for the quarter was down 10.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.87 earnings per share. Analysts predict that Danaher Co. will post 7.63 EPS for the current year.

Danaher Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, April 26th. Investors of record on Thursday, March 28th will be paid a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.43%. This is a positive change from Danaher’s previous quarterly dividend of $0.24. The ex-dividend date of this dividend is Wednesday, March 27th. Danaher’s dividend payout ratio is presently 15.02%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.